Patients with retinal vein occlusion-related macular edema had a higher likelihood of blindness and low vision if they had low best-corrected visual acuity after 1 month of intravitreal treatment.
Perfuse Therapeutics has reported 24-week data from its first-in-human, multi-centre Phase I/IIa trial of the PER-001 intravitreal implant for individuals with glaucoma. The trial of PER-001 is ...
SAN FRANCISCO, April 21, 2025 /PRNewswire/ -- Perfuse Therapeutics, Inc. ("Perfuse Therapeutics"), a biopharmaceutical company pioneering transformational therapies to treat ischemia-induced ocular ...
The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...
CHICAGO — Topical antibiotic prophylaxis is completely unnecessary in association with intravitreal injections, according to findings from more than 15,000 injections by a single surgeon who presented ...
Seven different postoperative complications occurred two to four times more often in patients who had a history of intravitreal drug injections as compared with those who did not. Among complications ...
Please provide your email address to receive an email when new articles are posted on . The development of drug delivery platforms that offer sustained release of therapeutic agents in the retina ...
PER-001 is a novel (new chemical entity), first-in-class small molecule endothelin receptor antagonist. Endothelin is the most potent vasoconstrictor in the human body and is upregulated in glaucoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback